PA
Passage Bio, Inc.
PASG · NASDAQ
$4.95 +2.17% (+$0.11)
1M +9.76%
Market Cap $15.9M
P/E Ratio -
Div. Yield -
ROE 218.59%
Bulios Fair Price
$4.46
9.9% downside
Current Price
$4.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PASG is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
57 /100
Fair P/B 3.57x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 54.67%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 889.92%
ROE 218.59%
ROA 143.44%
Debt
84 /100
Low Debt/Equity 0.00x
Current ratio 1.22x
Int. coverage N/A
Stability
58 /100
Moderate Beta 1.43x
EPS volatility 8.56%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PASG
Online
Sector
Healthcare
Industry
Biotechnology
CEO
William Chou
Employees
24
Headquarters
Philadelphia
Upcoming events
09 NOV
Earnings
Upcoming earnings report